Chinese biotech developing antibody-drug conjugates for cancer, with licensing deals with Merck, BMS and Novartis.
Chinese biotech developing antibody-drug conjugates for cancer, with licensing deals with Merck, BMS and Novartis.
No product sales yet: income is upfront payments and milestones from drug partners that license its ADCs (antibody-drug conjugates, which carry a toxic payload to cancer cells), and the cash from those deals funds its own trials. BioNTech holds rights to its two lead ADCs.
In one line: A Chinese Seagen/ImmunoGen-style ADC developer.
Moat: narrow (IP / patents, process know-how). Differentiated ADC linker-payload technology validated by multiple global pharma licensing deals.
Headquarters: Shanghai, China · Employees: 231
Size Duality Biotherapeutics (9606.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $1.06B, the 571st largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$91.10 on 18 Nov 2026.
Performance Over six months the shares fell 57.7%, against -16.6% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — lowest of 20 in its peer set.
Growth Revenue fell 4.6% over the last twelve months (peer median +1.1%); the operating margin is -180.6% (peer median -2.5%).
Valuation It trades at 5.6× enterprise value to sales against a peer median of 6.2× (7th cheapest of 14).
Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$932M | HK$2.01B | HK$2.10B | HK$1.97B | HK$1.86M |
| Revenue growth | — | -5% | +7% | +106,001% | — |
| Gross profit | -HK$276M | HK$631M | HK$842M | HK$1.50B | -HK$226,761 |
| EBITDA | -HK$1.67B | -HK$489M | -HK$220M | HK$820M | -HK$428M |
| Net income | -HK$1.62B | -HK$2.81B | -HK$1.14B | -HK$395M | -HK$450M |
| Free cash flow | -HK$921M | HK$197M | HK$308M | HK$890M | -HK$351M |
| Capital expenditure | HK$18.6M | HK$14.9M | HK$33.8M | HK$39.7M | HK$25.8M |
| Total debt | n/a | HK$181M | HK$3.25B | HK$2.35B | HK$1.21B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Duality Biotherapeutics 9606.HK | $1.06B | -58% | -5% | -181% | 5.6× | n/a |
| Innovent Biologics 1801.HK | $18.9B | +4% | +43% | 17% | 7.3× | 11.6% |
| RemeGen 9995.HK | $6.07B | -28% | +293% | 61% | 4.4× | -6.8% |
| Sichuan Kelun-Biotech Biopharmaceutical 6990.HK | $13.0B | -1% | +44% | -38% | 41.4× | 55.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 9606.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -46.0% | -8.6% | lowest of 21 |
| 6-month return | -57.7% | -16.6% | lowest of 20 |
| Distance from 52-week high | -75.8% | -40.8% | lowest of 21 |
| Revenue growth (TTM) | -4.6% | +1.1% | 6th lowest of 14 |
| Operating margin | -180.6% | -2.5% | 3rd lowest of 14 |
| EV / Sales | 5.6× | 6.2× | 7th cheapest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Duality Biotherapeutics 9606.HK | Hong Kong | $1.06B | -58% | -5% | -181% | 5.6× | n/a | n/a |
| Jade Biosciences JBIO | United States | $1.07B | -34% | n/a | n/a | n/a | n/a | n/a |
| Daan Gene 002030.SZ | China | $1.05B | -17% | +1% | -81% | 8.0× | 4.8% | -32.3% |
| Guangzhou Wondfo Biotech 300482.SZ | China | $1.05B | -18% | -24% | -2% | 2.9× | 14.3% | -5.8% |
| Alto Neuroscience ANRO | United States | $1.04B | +25% | n/a | n/a | n/a | n/a | n/a |
| Vor Biopharma VOR | United States | $1.10B | +15% | n/a | n/a | n/a | n/a | n/a |
| Inhibrx Biosciences INBX | United States | $1.02B | -37% | +43% | -6,287% | 551.0× | n/a | n/a |
| SpyGlass Pharma SGP | United States | $993M | +36% | n/a | n/a | n/a | n/a | n/a |
| Changchun BCHT Biotechnology 688276.SS | China | $992M | -2% | +2% | -29% | 9.9× | n/a | n/a |
| COMPASS Pathways Plc Sponsored ADR CMPS | United States | $1.15B | -25% | n/a | n/a | n/a | n/a | n/a |
| Kardigan KARD | United States | $1.15B | n/a | n/a | n/a | n/a | n/a | n/a |
| Akums Drugs and Pharmaceuticals AKUMS.NS | India | $1.21B | +38% | +18% | 10% | 2.0× | 15.3% | +9.9% |
| Mineralys Therapeutics MLYS | United States | $1.22B | -52% | n/a | n/a | n/a | n/a | n/a |
| Liaoning Chengda Biotechnology 688739.SS | China | $1.22B | -14% | -9% | 0% | 2.2× | 6.6% | -7.0% |
| China Animal Husbandry Industry 600195.SS | China | $921M | -16% | +1% | 2% | 1.3× | 6.1% | +4.4% |
| Innovita Biological Technology 688253.SS | China | $915M | -28% | -28% | 11% | 14.0× | 39.6% | -16.6% |
| Odyssey Therapeutics ODTX | United States | $912M | +12% | -33% | -5,415% | 204.9× | n/a | n/a |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.24B | -21% | +1% | 10% | 3.5× | n/a | n/a |
| Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ | China | $909M | -15% | 0% | 22% | 4.2× | 9.2% | +2.3% |
| Hualan Biological Vaccine 301207.SZ | China | $1.25B | -29% | -28% | -7% | 9.0× | 33.2% | -13.1% |
| GNI 2160.T | Japan | $903M | -25% | +44% | -21% | 6.2× | n/a | n/a |